Recurrent exon-deleting activating mutations in AHR act as drivers of urinary tract cancer

Bladder cancer has a high recurrence rate and low survival of advanced stage patients. Few genetic drivers of bladder cancer have thus far been identified. We performed in-depth structural variant analysis on whole-genome sequencing data of 206 metastasized urinary tract cancers. In ~ 10% of the pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Vlaar, Judith M., Borgman, Anouska, Kalkhoven, Eric, Westland, Denise, Besselink, Nicolle, Shale, Charles, Faltas, Bishoy M., Priestley, Peter, Kuijk, Ewart, Cuppen, Edwin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203531/
https://www.ncbi.nlm.nih.gov/pubmed/35710704
http://dx.doi.org/10.1038/s41598-022-14256-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203531/
https://www.ncbi.nlm.nih.gov/pubmed/35710704
http://dx.doi.org/10.1038/s41598-022-14256-0

Ejemplares similares